InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
4,967.23
(
-0.88%
)
US TECH 100
16,554.00
(
-2.26%
)
Dow Jones
37,986.40
(
0.56%
)
Brent Oil
86.63
(
0.00%
)
Bitcoin
64,061.14
(
0.35%
)
Post# of 1434
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

rikic

Send PM Follow Ignore
Followers 2
Posts 298
Boards Moderated 0
Alias Born 08/16/2010

rikic

Re: None

Tuesday, 10/03/2017 7:53:23 AM

Tuesday, October 03, 2017 7:53:23 AM

Post# of 1434
Key financials in the licensing ageement:
Partnership with Grifols, S.A.

* The royalty rate is 12.5% on the first $300 milion of annual sales for all territories and all indications, and 20% for annual sales in excess of $300 milion

* $20 milion in pre-approval and approval milestones remaining

* Aradigm responsible for the product supply

Aradigm believes the NCFBE indication for Linhaliq exceed $500MM of sales by 2021. Ladenburhg analysts project $1B sales by 2022, Nektar projected $750 milion for their NCFBE product with Bayer.




Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up